Previous 10 | Next 10 |
Annovis Bio to Present at the Alzheimer's Association International Conference PR Newswire Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings , ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips AMC Entertainment (NYSE: AMC ) stock is in the news today as investors in the movie theater company prepare for a potential catalyst coming next month! AMC Entertainment announced that it will release its earnings r...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Annovis Bio (NYSE: ANVS ) stock is soaring higher on Thursday following a positive update from the U.S. Food and Drug Administration (FDA) for its buntanetap clinical trial . Buntanetap i...
Target Hospitality ( TH ) +22% e xpanded partnership with Leading National Nonprofit Supporting Critical Humanitarian Aid Solutions. Annovis Bio ( ANVS ) +17% wins FDA nod to begin late-stage study for Parkinson's candidate. Grove Collaborative Holdings...
Clinical-stage biotech Annovis Bio ( NYSE: ANVS ) added ~10% in the pre-market Thursday after the company announced that the FDA gave the go-ahead to a Phase 3 trial for oral experimental therapy buntanetap for the treatment of Parkinson's disease. Following a Type B m...
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease PR Newswire FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease BERWYN, Pa. , ...
Mid- and late-stage data readouts over the last few years for Alzheimer's therapies have had a similar theme: Failure. Almost all these candidates have one thing in common: They target reducing beta-amyloid plaque in the brain that is thought to play a role in the memory-robbing dis...
Annovis Bio (NYSE:ANVS) on Thursday said it submitted an international patent application under the Patent Cooperation Treaty for its drug platform buntanetap. The patent claims method of preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasit...
Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections PR Newswire Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegen...
Gainers: DBV Technologies (DBVT) +21%. Rubius Therapeutics (RUBY) +20%. Annovis Bio (ANVS) +17%. LumiraDx (LMDX) +16%. CTI BioPharma (CTIC) +15%. Losers: Rigel Pharmaceuticals (RIGL) -48%. Cosmos (COSM) -13%. Accelerate Diagnostics (AXDX) ...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...